Farydak
NICE publishes new myeloma guidance
February 10, 2016Medical Communications, Research and Development Farydak, Novartis, multiple myeloma
NICE has set out best practice for the diagnosis, monitoring and treatment of myeloma, in new guidelines published today. Myeloma …
NICE backtracks on Novartis Farydak decision
December 4, 2015Medical Communications, Sales and Marketing Farydak, NICE, Novartis, panobinostat
NICE has reversed its earlier decision to reject the Novartis drug Farydak as an NHS treatment for people with multiple …
NICE rejects Farydak for multiple myeloma
September 16, 2015Sales and Marketing Farydak, NICE, Novartis, multiple myeloma, panobinostat
NICE has rejected Novartis Farydak in its draft guidance, ruling it out as a treatment for multiple myeloma. Farydak (panobinostat) is …
Novartis blood cancer drug Farydak receives EU approval
September 4, 2015Sales and Marketing Cancer, European Commission, Farydak, Novartis, multiple myeloma, myeloma, panobinostat
The European Commission has approved Novartis’s Farydak, in combination with Velcade and dexamethasone, for the treatment of adult patients with …
FDA in Novartis cancer drug U-turn
February 24, 2015Research and Development, Sales and Marketing Cancer, FDA, Farydak, Novartis, Revlimid, Velcade, myeloma
The FDA has overturned an earlier advisory committee recommendation and decided to approve Novartis’ blood cancer drug Farydak. In November …
Priority review for Novartis myeloma drug
November 26, 2014Sales and Marketing FDA, Farydak, Novartis, daratumumab, elotuzumab, myeloma, odac
Novartis’ multiple myeloma treatment Farydak has been given an extended review by the FDA after its future seemed in jeopardy …
Future bleak for Novartis’ myeloma drug
November 21, 2014Medical Communications FDA, Farydak, Novartis, ixazomib, myeloma, panobinostat
Novartis suffered a major disappointment with the negative FDA panel vote for multiple myeloma candidate Farydak earlier this month, but …
